Citigroup’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Citigroup’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-700	Closed	-$5K	–	7296
2016 Q2	$5K	Sell	700 -43	-6%	-$303	﹤0.01%	6798
2016 Q1	$5K	Buy	743 +43	+6%	+$316	﹤0.01%	7032
2015 Q4	$7K	Sell	700 -200	-22%	-$2.32K	﹤0.01%	6947
2015 Q3	$11K	Sell	900 -416	-32%	-$4.6K	﹤0.01%	6401
2015 Q2	$12K	Sell	1,316 -3	-0.2%	-$23	﹤0.01%	6386
2015 Q1	$8K	Sell	1,319 -622	-32%	-$3.85K	﹤0.01%	6574
2014 Q4	$11K	Buy	1,941 +321	+20%	+$1.87K	﹤0.01%	6459
2014 Q3	$10K	Sell	1,620 -180	-10%	-$1.1K	﹤0.01%	6291
2014 Q2	$12K	Sell	1,800 -296	-14%	-$1.98K	﹤0.01%	6097
2014 Q1	$15K	Buy	2,096 +296	+16%	+$2.04K	﹤0.01%	6184
2013 Q4	$12K	Buy	+1,800	New	+$12.3K	﹤0.01%	6370

Other funds holding JNP

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Citigroup's JNP Position: Q3 2016 in Review

Citigroup sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2016, closing a stake of 700 shares — an estimated $5K sold.

Citigroup first reported a position in JNP in Q4 2013 and held it in 11 quarters. The position peaked at $15K in Q1 2014. 46 funds tracked by Wall St. Rank hold JNP as of Q3 2016.

Citigroup reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Citigroup sold 700 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2016, an estimated $5K.
Citigroup first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q4 2013 and held it in 11 quarters.
Citigroup's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $15K in Q1 2014.
46 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2016.

Based on Citigroup's 13F filing for Q3 2016, filed 10 Nov 2016.